CA2898565C - Treatment of graft versus host disease in transplant patients - Google Patents

Treatment of graft versus host disease in transplant patients Download PDF

Info

Publication number
CA2898565C
CA2898565C CA2898565A CA2898565A CA2898565C CA 2898565 C CA2898565 C CA 2898565C CA 2898565 A CA2898565 A CA 2898565A CA 2898565 A CA2898565 A CA 2898565A CA 2898565 C CA2898565 C CA 2898565C
Authority
CA
Canada
Prior art keywords
compound
conditioning
hsct
days
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2898565A
Other languages
English (en)
French (fr)
Other versions
CA2898565A1 (en
Inventor
Peter Gergely
Kazuhiko Kuriyama
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Priothera Ltd
Original Assignee
Priothera Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Priothera Ltd filed Critical Priothera Ltd
Publication of CA2898565A1 publication Critical patent/CA2898565A1/en
Application granted granted Critical
Publication of CA2898565C publication Critical patent/CA2898565C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01B—SOIL WORKING IN AGRICULTURE OR FORESTRY; PARTS, DETAILS, OR ACCESSORIES OF AGRICULTURAL MACHINES OR IMPLEMENTS, IN GENERAL
    • A01B1/00—Hand tools
    • A01B1/02—Spades; Shovels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/28—Mercury; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/31—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/32—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton having at least one of the nitrogen atoms bound to an acyclic carbon atom of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/094—Esters of phosphoric acids with arylalkanols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Cardiology (AREA)
  • Environmental Sciences (AREA)
  • Soil Sciences (AREA)
  • Mechanical Engineering (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2898565A 2013-02-20 2014-02-18 Treatment of graft versus host disease in transplant patients Active CA2898565C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361766830P 2013-02-20 2013-02-20
US61/766,830 2013-02-20
PCT/IB2014/059067 WO2014128611A1 (en) 2013-02-20 2014-02-18 Treatment of graft versus host disease in transplant patients

Publications (2)

Publication Number Publication Date
CA2898565A1 CA2898565A1 (en) 2014-08-28
CA2898565C true CA2898565C (en) 2023-01-24

Family

ID=50236228

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2898565A Active CA2898565C (en) 2013-02-20 2014-02-18 Treatment of graft versus host disease in transplant patients

Country Status (23)

Country Link
US (2) US20160000811A1 (enExample)
EP (1) EP2958624B1 (enExample)
JP (2) JP6441822B2 (enExample)
KR (1) KR102165514B1 (enExample)
CN (1) CN105007981B (enExample)
AU (1) AU2014220377B2 (enExample)
BR (1) BR112015019197A2 (enExample)
CA (1) CA2898565C (enExample)
CY (1) CY1124191T1 (enExample)
DK (1) DK2958624T3 (enExample)
EA (1) EA030783B1 (enExample)
ES (1) ES2873181T3 (enExample)
HR (1) HRP20210891T1 (enExample)
HU (1) HUE054330T2 (enExample)
LT (1) LT2958624T (enExample)
MX (1) MX369631B (enExample)
PL (1) PL2958624T3 (enExample)
PT (1) PT2958624T (enExample)
RS (1) RS61933B1 (enExample)
SI (1) SI2958624T1 (enExample)
SM (1) SMT202100334T1 (enExample)
TW (1) TWI648050B (enExample)
WO (1) WO2014128611A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017231000B2 (en) * 2016-03-08 2023-06-29 Priothera Limited Treatment of hematopoietic stem cell transplant patients
CN112512516A (zh) * 2018-07-27 2021-03-16 普瑞奥治疗有限公司 用于在已经经历造血干细胞移植的患者中抑制血液恶性肿瘤复发的活性剂
CN117177748A (zh) * 2020-11-04 2023-12-05 浩康生物系统公司 用于异基因造血干细胞移植的方法
KR20230136603A (ko) 2021-01-28 2023-09-26 프리오테라 에스에이에스 S1p 수용체 조정제를 사용한 치료 방법
WO2022162409A1 (en) 2021-01-28 2022-08-04 Priothera Sas Methods of treatment with s1p receptor modulators
TW202341971A (zh) 2022-02-16 2023-11-01 法商普萊歐塞拉公司 使用car細胞及s1p受體調節劑之治療方法
EP4282407A1 (en) 2022-05-27 2023-11-29 Priothera SAS Treatment of cancer with s1p receptor agonists
WO2025109119A1 (en) 2023-11-22 2025-05-30 Priothera Sas Methods of treatment with multispecific antigen-binding proteins in combination with s1p receptor modulators

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002514193A (ja) * 1996-11-15 2002-05-14 バクスター、インターナショナル、インコーポレイテッド 同種幹細胞移植のためのコンディショニング
US6383481B1 (en) 1998-03-30 2002-05-07 Japan Immunoresearch Laboratories Co., Ltd. Method for transplantation of hemopoietic stem cells
JPH11343242A (ja) * 1998-03-30 1999-12-14 Otsuka Pharmaceut Co Ltd 造血幹細胞移植用剤
AU2002332289B2 (en) * 2001-09-27 2007-05-10 Kyorin Pharmaceutical Co., Ltd. Diaryl sulfide derivative, addition salt thereof, and immunosuppressant
AU2003264430B2 (en) * 2002-09-19 2009-03-19 Kyorin Pharmaceutical Co., Ltd. Amino alcohol derivative, addition salt thereof, and immunosuppressant
ATE502630T1 (de) * 2004-07-16 2011-04-15 Kyorin Seiyaku Kk Verfahren zur effektiven anwendung eines medikaments und verfahren zur prävention von nebenwirkungen
JP4966019B2 (ja) * 2005-01-06 2012-07-04 キッセイ薬品工業株式会社 慢性移植片対宿主症におけるドライアイの予防および治療剤
WO2011140170A1 (en) 2010-05-04 2011-11-10 Yeda Research And Development Co. Ltd. Immunotherapy using redirected allogeneic cells
AU2011249789B2 (en) 2010-05-06 2015-03-19 Novartis Ag Dosage regimen of diaryl sulfide derivatives

Also Published As

Publication number Publication date
AU2014220377B2 (en) 2017-05-04
CA2898565A1 (en) 2014-08-28
MX369631B (es) 2019-11-14
US20180153911A1 (en) 2018-06-07
EP2958624B1 (en) 2021-05-12
HUE054330T2 (hu) 2021-09-28
HRP20210891T1 (hr) 2021-07-23
US11224604B2 (en) 2022-01-18
CN105007981A (zh) 2015-10-28
CY1124191T1 (el) 2022-05-27
TWI648050B (zh) 2019-01-21
TW201511751A (zh) 2015-04-01
EA201591522A1 (ru) 2016-03-31
JP2016509050A (ja) 2016-03-24
EA030783B1 (ru) 2018-09-28
KR102165514B1 (ko) 2020-10-15
BR112015019197A2 (pt) 2017-07-18
MX2015010833A (es) 2016-07-08
PT2958624T (pt) 2021-06-11
JP6441822B2 (ja) 2018-12-19
DK2958624T3 (da) 2021-06-07
EP2958624A1 (en) 2015-12-30
JP2019059748A (ja) 2019-04-18
US20160000811A1 (en) 2016-01-07
RS61933B1 (sr) 2021-07-30
ES2873181T3 (es) 2021-11-03
LT2958624T (lt) 2021-08-10
CN105007981B (zh) 2020-07-21
SI2958624T1 (sl) 2021-07-30
WO2014128611A1 (en) 2014-08-28
KR20150118149A (ko) 2015-10-21
AU2014220377A1 (en) 2015-08-06
JP6633170B2 (ja) 2020-01-22
SMT202100334T1 (it) 2021-07-12
PL2958624T3 (pl) 2021-10-04

Similar Documents

Publication Publication Date Title
US11224604B2 (en) Treatment of graft versus host disease in transplant patients
JP7788114B2 (ja) ヒトにおける固形腫瘍の処置のためのＣ．ｎｏｖｙｉ
JP6453441B2 (ja) 骨髄異形成症候群を治療するためのタンパク質ホスファターゼ２ａ阻害剤
JP2023080357A (ja) リンパ球悪性疾患を治療するための方法
JP2016509050A5 (enExample)
Raderer et al. Role of chemotherapy in gastric MALT lymphoma, diffuse large B-cell lymphoma and other lymphomas
JP2024506825A (ja) Ｓ１ｐ受容体調節剤による処置の方法
CN117797149A (zh) 西达本胺联合r-chop的应用及联合药物
WO2012151541A1 (en) Csf-1r inhibitors for treatment of brain tumors
TWI772992B (zh) 作為bcl-2抑制劑的n-(苯基磺醯基)苯甲醯胺及相關化合物
JP2020532555A (ja) ダントロレンを使用して神経薬暴露を治療する方法
EP3426279B1 (en) Treatment of hematopoietic stem cell transplant patients
TW202102211A (zh) 用於使用６，８－雙－苄硫基－辛酸治療淋巴瘤之治療方法及組成物
CN111195250A (zh) 西达本胺联合dice的应用及联合药物
EP3265075B1 (en) Roneparstat combined therapy of multiple myeloma
EA052496B1 (ru) Фармацевтическая композиция, содержащая модулятор рецептора s1p, и способ ее получения
HK40025659B (en) Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment
HK40025659A (en) Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20181130

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250123

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250123

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250123

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD

Year of fee payment: 12

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260122

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260122